http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-119651-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_42dcb8afd289e295b65f450020cbfdb4 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D495-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D491-048 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D491-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D491-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5025 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4985 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D519-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D495-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5025 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4985 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D498-08 |
| filingDate | 2019-06-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fc3a72b7e6e06edd30f022f5dd34c09f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0b35728fd1427f59ef29394dcf816e4a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_eef1a318780834b07b9ef8d76c322e0b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a0a5e6bbd2508725d71c47449696d81c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cb61348f029a9ec631da8bb754408e6b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0e7010b56bad6fa8f22dd8aa21041abb http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0686cde8ec21cf76f55d2e947fd5e450 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7e1a3b5479df671d71037f79149eef87 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f94fcad1ab73e5a67f983817d32f1822 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7fc4bac36d3344b3c640f24a27022735 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4199f8dfeff1c4932c563742f240b2bc http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_34b396def16c363f209c7ef39cb4afbd http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_43829a6d4983e7789f1cb0f471aad459 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9a517de2506ec2dcfc854fcb335fa94c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0305f8f652cccd3608c4c6092fb88235 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_01e7eee5fe9cdd255b73575d28787f9d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1a06235961b70e50abc7ba6dd08b31cc |
| publicationDate | 2022-01-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-119651-A1 |
| titleOfInvention | HETEROCYCLIC AND HETEROARYL COMPOUNDS TO TREAT HUNTINGTON'S DISEASE |
| abstract | Condensed pyridazine and pyrazine derivative heterocyclic compounds and pharmaceutical compositions comprising them all of which are used for the treatment of Huntington's disease (HD) are provided. Claim 1: A compound comprising, a compound of formula (1) or a form thereof, wherein: dashed lines represent one or more double bonds optionally present where permitted by available valences; W¹ is independently C-Rᵃ, CH-Rᵃ, N, N-Rᵇ, O or S where allowed by the available valences; W² is independently C-Rᵃ, CH-Rᵃ, N, or N-Rᵇ where allowed by available valences, and; W³ is independently C, CH or N where permitted by available valences; wherein at least one of W¹, W² or W³ is N or N-Rᵇ; W⁴ and W⁵ are independently C-Rᵃ or N, where when W¹ is S or O, W² is C-Rᵃ, and W³ is C; Rᵃ is in each case independently selected from hydrogen, cyano, halogen, hydroxy, C₁₋₆-alkyl, deutero-C₁₋₄-alkyl, halo-C₁₋₆-alkyl, C₁₋₆-alkoxy, halo-C₁₋₆-alkoxy, alkoxy C₁₋₆-C₁₋₆-alkyl, amino, C₁₋₆-alkylamino, (C₁₋₆-alkyl)₂-amino, amino-C₁₋₆-alkyl, and hydroxy-C₁₋₆-alkyl; Rᵇ is selected from hydrogen and C₁₋₆ alkyl; R¹ is selected from C₃₋₁₀ cycloalkyl and heterocyclyl, where heterocyclyl is a 3-7 membered monocyclic, 6-10 membered bicyclic or 13-16 membered polycyclic, saturated or partially unsaturated ring system having 1, 2 or 3 ring member heteroatoms independently selected from N, O or S, and wherein each occurrence of C₃₋₁₀ cycloalkyl and heterocyclyl is optionally substituted with one, two or three R³ substituents and optionally with an additional R⁴ substituent, or, wherein, alternatively, each occurrence of C₃₋₁₀ cycloalkyl and heterocyclyl is optionally substituted with one, two, three or four R³ substituents; R² is selected from phenyl, heterocyclyl and heteroaryl, wherein heterocyclyl is a 3-7 membered monocyclic, 6-10 membered bicyclic or 13-16 membered polycyclic, saturated or partially unsaturated ring system having 1, 2 or 3 membered heteroatoms in the ring independently selected from N, O or S, where heteroaryl is a 3-7 membered monocyclic or 6-10 membered bicyclic ring system having 1, 2, 3 or 4 membered heteroatoms in the ring independently selected from N, O or S, and wherein each occurrence of phenyl, heterocyclyl and heteroaryl is optionally substituted with one, two or three R⁵ substituents, and optionally with one additional R⁶ substituent; R³ is each independently selected from cyano, halogen, hydroxy, C₁₋₆-alkyl, deutero-C₁₋₄-alkyl, halo-C₁₋₆-alkyl, C₁₋₆-alkoxy, halo-C₁₋₆-alkoxy, C₁₋-alkoxy ₆-C₁₋₆-alkyl, amino, C₁₋₆-alkylamino, (C₁₋₆-alkyl)₂-amino, amino-C₁₋₆-alkyl, and hydroxy-C₁₋₆-alkyl; R⁴ is selected from C₃₋₁₀ cycloalkyl, phenyl, heteroaryl and heterocyclyl, wherein heterocyclyl is a 3-7 membered monocyclic, 6-10 membered bicyclic or 13-16 membered polycyclic, saturated or partially unsaturated ring system, which has 1, 2 or 3 membered heteroatoms in the ring independently selected from N, O or S, where heteroaryl is a 3-7 membered monocyclic or 6-10 membered bicyclic ring system having 1, 2, 3 or 4 heteroatom ring members independently selected from N, O or S, and wherein each occurrence of C₃₋₁₀ cycloalkyl, phenyl, heterocyclyl and heteroaryl is optionally substituted with one, two or three R⁷ substituents; R⁵ is in each case independently selected from halogen, hydroxy, cyano, nitro, C₁₋₆ alkyl, deutero-C₁₋₄ alkyl, halo-C₁₋₆ alkyl, C₁₋₆ alkoxy, halo-C₁₋₆ alkoxy, oxime , amino, C₁₋₆-alkylamino, (C₁₋₆-alkyl)₂-amino and C₁₋₆-alkyl-thio; R⁶ is selected from phenyl and heteroaryl, wherein heteroaryl is a 3-7 membered monocyclic or 6-10 membered bicyclic ring system having 1, 2, 3 or 4 membered heteroatoms in the ring independently selected from N, O or S, and wherein each occurrence of phenyl and heteroaryl is optionally substituted with one, two, three or four R⁸ substituents; R⁷ is each independently selected from cyano, halogen, hydroxy, C₁₋₆-alkyl, deutero-C₁₋₄-alkyl, halo-C₁₋₆-alkyl, C₁₋₆-alkoxy, halo-C₁₋₆-alkoxy, C₁₋-alkoxy ₆-C₁₋₆-alkyl, amino, C₁₋₆-alkylamino, (C₁₋₆-alkyl)₂-amino, amino-C₁₋₆-alkyl and C₃₋₁₀-cycloalkyl; and R⁸ is each independently selected from cyano, halogen, hydroxy, C₁₋₆ alkyl, deutero-C₁₋₄ alkyl, halo-C₁₋₆ alkyl, C₁₋₆ alkoxy, halo-C₁₋₆ alkoxy, C₁ alkoxy ₋₆-C₁₋₆-alkyl, amino, C₁₋₆-alkylamino, (C₁₋₆-alkyl)₂-amino, amino-C₁₋₆-alkyl and C₃₋₁₀-cycloalkyl; wherein a form of the compound is selected from the group consisting of salt, hydrate, solvate, racemate, enantiomer, diastereomer, stereoisomer, and tautomeric form thereof. |
| priorityDate | 2018-06-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 51.